NASDAQ
OSMT

Osmotica Pharmaceuticals plc

Prices are adjusted according to historical splits.

Osmotica Pharmaceuticals plc Stock Price

Vitals

Today's Low:
$
Today's High:
$
Open Price:
$
52W Low:
$2.81
52W High:
$7.97
Prev. Close:
$
Volume:

Company Statistics

Market Cap.:
$0.390 billion
Book Value:
2.228
Revenue TTM:
$0.212 billion
Operating Margin TTM:
4.23%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
-73.47%
Return on Assets TTM:
1.01%
Return on Equity TTM:
-79.95%

Company Profile

Osmotica Pharmaceuticals plc had its IPO on 2018-10-18 under the ticker symbol OSMT.

The company operates in the sector and industry. Osmotica Pharmaceuticals plc has a staff strength of 379 employees.

Stock update

Shares of Osmotica Pharmaceuticals plc opened at $0 at the start of the last trading session i.e. .

The stocks traded within a range of $0 - $0, and closed at $0.

This is a 0% increase from the previous day's closing price.

A total volume of 0 shares were traded at the close of the day’s session.

In the last one week, shares of Osmotica Pharmaceuticals plc have increased by 0%.

Osmotica Pharmaceuticals plc's Key Ratios

Osmotica Pharmaceuticals plc has a market cap of $0.390 billion, indicating a price to book ratio of 2.4118 and a price to sales ratio of 1.296.

In the last 12-months Osmotica Pharmaceuticals plc’s revenue was $0.212 billion with a gross profit of $0.000 billion and an EBITDA of $0.034 billion. The EBITDA ratio measures Osmotica Pharmaceuticals plc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Osmotica Pharmaceuticals plc’s operating margin was 4.23% while its return on assets stood at 1.01% with a return of equity of -79.95%.

In Q2, Osmotica Pharmaceuticals plc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 34.8%.

Osmotica Pharmaceuticals plc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
None

Its diluted EPS in the last 12-months stands at $-2.806 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of None. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Osmotica Pharmaceuticals plc’s profitability.

Osmotica Pharmaceuticals plc stock is trading at a EV to sales ratio of 2.1167 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 1.296.

Osmotica Pharmaceuticals plc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Osmotica Pharmaceuticals plc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Osmotica Pharmaceuticals plc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Osmotica Pharmaceuticals plc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Osmotica Pharmaceuticals plc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Osmotica Pharmaceuticals plc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$0
52-Week High
$7.97
52-Week Low
$2.81
Analyst Target Price
$9.33

Osmotica Pharmaceuticals plc stock is currently trading at $0 per share. It touched a 52-week high of $7.97 and a 52-week low of $7.97. Analysts tracking the stock have a 12-month average target price of $9.33.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 4.97 indicating a short percent outstanding of 3%.

Around 4403.8% of the company’s stock are held by insiders while 4410.2% are held by institutions.

Frequently Asked Questions About Osmotica Pharmaceuticals plc

The stock symbol (also called stock or share ticker) of Osmotica Pharmaceuticals plc is OSMT

The IPO of Osmotica Pharmaceuticals plc took place on 2018-10-18

Similar Industry Stocks ()

Last Price
Chg
Chg%
$6.67
-0.09
-1.4%
$1.66
-0.05
-2.92%
$11.13
-0.38
-3.3%
Woodward Inc (WWD)
$90.35
-2
-2.17%
Brainsway Ltd (BWAY)
$3.54
0.03
+0.85%
$220.1
-8.07
-3.54%
$11.16
0.48
+4.49%
$29.57
-0.25
-0.84%
$172.4
-19.34
-10.09%
$59.43
2.26
+3.95%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products in the United States, Argentina, and Hungary. The company’s promoted products include M-72, a methylphenidate hydrochloride extended-release tablet to treat attention deficit hyperactivity disorder (ADHD); Osmolex ER, an amantadine extended-release tablet for the treatment of Parkinson’s and drug-induced extrapyramidal reactions in adults; Lorzone, a chlorzoxazone scored tablet for muscle spasms; ConZip, a tramadol hydrochloride extended-release capsule to treat pain; and Arbaclofen tablets which is in phase III clinical trial for the treatment of multiple sclerosis spasticity. It also provides women’s health products, including Divigel for menopause, as well as OB Complete, a dietary supplement for prenatal, pregnancy, and postnatal periods; and RVL-1201, an oxymetazoline hydrochloride ophthalmic solution for the treatment of Blepharoptosis. In addition, the company’s non-promoted products comprise methylphenidate ER tablets for ADHD; venlafaxine ER tablets to treat major depressive disorder and social anxiety disorder; hydromorphone ER for treating pain; nifedipine ER for hypertension; sodium benzoate/sodium phenylacetate for the treatment of hyperammonemia; oxybutynin ER for overactive bladder; and prescription prenatal vitamins for treating nutritional requirements during pregnancy, as well as Osmodex and other abbreviated new drug applications. Osmotica Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.

Address

400 Crossing Boulevard, Bridgewater, NJ, United States, 08807